Welcome to our dedicated page for IDEXX Laboratories SEC filings (Ticker: IDXX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IDEXX Laboratories, Inc. (IDXX) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a NASDAQ-listed, S&P 500 company focused on pet healthcare innovation, veterinary diagnostics, and software, IDEXX uses SEC filings to report financial results, material agreements, and governance changes that matter to shareholders and analysts.
Among the most closely watched documents are annual reports on Form 10‑K and quarterly reports on Form 10‑Q, which describe IDEXX’s business, risk factors, and detailed financial statements, including performance in areas such as the Companion Animal Group, Water, and Livestock, Poultry and Dairy. Current reports on Form 8‑K provide timely updates on specific events, such as quarterly earnings releases, amendments to credit agreements, and board or leadership changes. For example, IDEXX has filed 8‑Ks describing an amendment to a credit agreement that provides unsecured revolving and term loan facilities for general corporate purposes, as well as filings that furnish earnings press releases.
Investors can also use this page to monitor proxy statements for information on board structure and executive compensation, and Form 4 insider transaction reports when available, which show purchases and sales of IDXX shares by directors and officers.
Stock Titan enhances these filings with AI-powered summaries that explain key points in plain language, helping users navigate lengthy documents such as 10‑Ks and 10‑Qs. Real-time updates from EDGAR mean new IDEXX filings appear promptly, while AI highlights important items like changes in leverage arrangements, governance updates, and trends in reported results. This makes it easier to understand how IDEXX’s regulatory disclosures relate to its veterinary diagnostics, software, and animal health businesses.
Lane Michael reported multiple insider transaction types in a Form 4 filing for IDXX. The filing lists transactions totaling 10,810 shares at a weighted average price of $629.35 per share. Following the reported transactions, holdings were 1,101 shares.
IDEXX Laboratories Executive Vice President Michael Perkins Johnson reported equity award activity and related share settlements. He received stock options for 3,207 shares (non-qualified) and 162 shares (incentive) on February 12, 2026, along with 770 restricted stock units (RSUs), all at a grant price of $0.00 per share.
On February 14, 2026, 176, 179 and 218 RSUs were exercised into the same number of common shares at $0.00 per share. In a separate tax-withholding disposition, 178 common shares were delivered at $629.35 per share to cover tax obligations, leaving him with 2,794.687 directly owned common shares.
IDEXX Laboratories Executive Vice President Nimrata Hunt reported multiple equity awards, vesting events, and related share withholdings. On February 12, 2026, Hunt received grants of 4,625 non-qualified stock options, 162 incentive stock options, and restricted stock units covering 1,094 and 1,620 shares of common stock.
On February 14, 2026, several restricted stock unit awards were exercised or converted, delivering a total of 2,587 shares of common stock, while 1,154 shares were withheld at $629.35 per share to satisfy tax obligations. After these transactions, Hunt directly owned 22,591.944 shares and indirectly held 160 shares jointly with a spouse.
IDEXX Laboratories Executive Vice President George Fennell reported a series of routine equity compensation transactions. On February 12, 2026, he received grants of 3,384 non-qualified stock options, 162 incentive stock options, and 810 restricted stock units (RSUs), each representing the right to receive one share of common stock as they vest over future years.
On February 14, 2026, previously granted RSUs vested and were converted into common shares through derivative exercises, and 199 common shares were withheld at $629.35 per share to satisfy tax obligations. After these transactions, Fennell directly held 10,078 shares of IDEXX common stock.
Erickson Michael G reported multiple insider transaction types in a Form 4 filing for IDXX. The filing lists transactions totaling 12,019 shares at a weighted average price of $629.35 per share. Following the reported transactions, holdings were 550 shares.
IDEXX Laboratories executive vice president, CFO and treasurer Andrew Emerson reported multiple equity compensation transactions. He exercised and converted several small lots of vested restricted stock units into common shares and had 123 shares of common stock disposed at $629.35 per share to cover tax obligations.
He also received new equity awards, including 4,270 non-qualified stock options and 162 incentive stock options, plus 729 and 284 restricted stock units. Footnotes state these options and RSUs vest in annual installments beginning on February 14, 2027, with some RSUs deferred under the company’s deferred compensation plan.
A holder of IDXX common stock has filed a Rule 144 notice to sell 1,464 shares through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $920,293.11. Shares of common stock outstanding were 79,851,330 as of the filing.
The shares to be sold were acquired through restricted stock grants of 257 shares on 05/06/2024 and 262 shares on 05/06/2025, and a stock option exercise of 945 shares for cash on 02/17/2026, all from the issuer.
IDEXX Laboratories (IDXX) filed a Form 144 notice for a planned sale of 5,371 shares of common stock. The shares are expected to be sold through Morgan Stanley Smith Barney LLC on or around 02/17/2026, with an indicated aggregate market value of $3,369,666.57.
The securities were acquired on 02/17/2026 via a stock option exercise from the issuer, paid in cash on the same date. The filing notes that 79,851,330 shares of common stock were outstanding, providing a baseline context for the size of this planned sale.
IDEXX Laboratories, Inc. reported that director M. Anne Szostak has notified the company of her intention to retire from its Board of Directors. Her retirement will be effective immediately following the company’s 2026 Annual Meeting of Stockholders, scheduled for May 12, 2026.
The company stated that Ms. Szostak’s decision does not result from any disagreement regarding operations, policies, or practices. She has served on the Board since 2012, and the company expressed appreciation for her contributions and leadership during this period.
Upon her retirement, the Board will reduce the size of Class III directors in line with its amended and restated by-laws. However, the overall Board size will not change because of the previously announced appointment of Michael G. Erickson, PhD as a Class II director immediately following the 2026 Annual Meeting.
IDEXX Laboratories Executive Vice President George Fennell exercised stock options and sold shares in recent transactions. On February 9 and 10, 2026, he exercised options covering 1,476 and 11,345 shares of common stock at an exercise price of $67.85 per share.
On February 10, 2026, Fennell then sold 11,345 shares of common stock in multiple open-market transactions at weighted average prices ranging from about $642.99 to $650.32 per share. After these trades, he directly beneficially owned 9,823 shares of IDEXX common stock.